Course Information
| Search by course code | Course Title | Search by faculty | Course Description | Date Display | Filter by day | Start | Finish | Filter by competency |
|---|---|---|---|---|---|---|---|---|
| S1870S | Masqueraders of Malignancy in Breast Pathology: Strategies and Solutions 1:30 PM – 4:00 PM CT |
Yunn-Yi Chen, MD, PhD, FCAP Timothy W. Jacobs, MD, FCAP yunn-yi.chen@ucsf.edu, Timothy.Jacobs@virginiamason.org |
Breast lesions that masquerade as malignancies frequently present diagnostic challenges for pathologists in their daily practice. Benign lesions mistaken for in situ or invasive carcinomas lead to false-positive diagnoses. This course will include common, as well as rarer, mimics of malignancy in breast pathology and provide diagnostic strategies and solutions useful in recognizing these potentially hazardous cases. Topics covered will include intraductal proliferative lesions, pseudoinvasive lesions, spindle cell lesions, metastases, nipple lesions, and lymph node mimickers. Faculty will use examples from their daily practice and consultation cases, utilizing a case-based format with audience interaction. Morphologic features will be emphasized throughout the course with integration of ancillary techniques (eg, IHC) highlighting their strengths and limitations. |
Saturday, October 10 | October 10 | 01:30 PM | 04:00 PM | Breast Pathology |
| S1950S | Intelligence Test: Implementing, Verifying, and Monitoring the Performance of Systems Incorporating Machine Learning and Artificial Intelligence 1:30 PM – 3:30 PM CT Matthew G. Hanna, MD, FCAP |
Matthew G. Hanna, MD, FCAP James H. Harrison Jr., MD, PhD, FCAP abdou.matthew@gmail.com, james.harrison@virginia.edu |
Systems that use machine learning and artificial intelligence can be powerful tools that extend pathologists’ capabilities, but how do we know they are performing well? What is required for initial validation and how should performance be monitored over time? Is proficiency testing required? What regulatory requirements are in development that target machine learning systems? This course will review common performance problems in machine learning and illustrate how to avoid them using best practices in performance assessment for initial deployment and maintenance of quality. The faculty will use a case set covering image analysis and predictive modeling to illustrate performance problems and their measurement, and stimulate a discussion of a regulatory environment appropriate for machine learning. |
Saturday, October 10 | October 10 | 01:30 PM | 03:30 PM | Informatics |
| S1956S | Point-of-Care Testing Pitfalls – What You Don’t Know Can Hurt You 1:30 PM – 3:30 PM CT |
Bradley S. Karon, MD, PhD, FCAP Deborah A. Perry, MD, FCAP Karon.bradley@mayo.edu, Deborah.Perry@nmhs.org |
Does your hospital have a point-of-care testing (POCT) program? Have you ever thought to yourself, “It’s only waived testing, what’s the big deal”? If you answered yes to these questions, this course is for you. The faculty will explore the laboratory medical director’s role in providing oversight to POCT programs and the regulatory expectations of the director. They will share real-life examples of common pitfalls of POCT programs and what that means to you, the director, when your POCT program falls victim to these pitfalls. Additionally, faculty will apply problem-solving techniques in group discussions to identify error prone steps in POCT, and tools that lab directors can use to address risk and improve the overall quality of POCT. This course will also provide team leaders and inspection team members with tips to conduct a fair and thorough inspection of a POCT program. |
Saturday, October 10 | October 10 | 01:30 PM | 03:30 PM | Laboratory Medical Direction |
| S2015C | Benign Mimics of Myelodysplastic Syndromes and Myeloproliferative Neoplasms: How to Avoid the Common Pitfalls 1:30 PM – 3:30 PM CT |
Olga Pozdnyakova, MD, PhD, FCAP Olga K. Weinberg, MD, FCAP opozdnyakova@bwh.harvard.edu, olga.weinberg@childrens.harvard.edu |
Don’t fall into the trap of overdiagnosing a myeloid neoplasm! Two expert hematopathologists will use a case-based approach to present a framework for approaching benign conditions of blood or marrow that present with alarming blood abnormalities, such as cytopenia (leukopenia, anemia, or thrombocytopenia) or cytoses (neutrophilia, lymphocytosis, or thrombocytosis), mimicking myelodysplastic syndrome or myeloproliferative neoplasms in adult and pediatric patients. The course will emphasize an algorithmic approach starting with peripheral blood morphologic clues that will be used to select appropriate ancillary studies, such as flow cytometry and genetic tests. The faculty will provide recommendations on how to avoid common pitfalls and not overdiagnose myeloid neoplasms. The course will be of interest for both practicing pathologists who review blood and bone marrow specimens daily as well as pathology residents and fellows. After completion of the course, participants will be well equipped to face the challenge of myeloid neoplasm look-alikes. |
Saturday, October 10 | October 10 | 01:30 PM | 03:30 PM | Hematology/Hematopathology |
| S2058C | From POLE to p53: Navigating the Molecular Genetics of Endometrial Tumors 1:30 PM – 3:00 PM CT |
Jessica L. Dillon, MD, FCAP Laura J. Tafe, MD, FCAP jessicaleigh.dillon@gmail.com, laura.j.tafe@hitchcock.org |
Classification of endometrial tumors based strictly on morphology can be challenging due to overlapping histologic features and often requires the assistance of ancillary testing. Recently proposed algorithms, such as the proactive molecular risk classifier for endometrial cancer (ProMisE), coupled with The Cancer Genome Atlas (TCGA) data, aim to further subclassify endometrial carcinomas into prognostically-significant groups based on molecular genetics. The faculty will examine the molecular classification of common endometrial tumors, including uterine serous, endometrioid and clear cell carcinomas, and mutations identified in precursor lesions. Attendees will recognize the clinical and prognostic implications of using molecular medicine to treat endometrial tumors and how best to communicate this information in reports. The course will utilize case studies and an interactive response system to engage the audience and reinforce key learning objectives. |
Saturday, October 10 | October 10 | 01:30 PM | 03:00 PM | Gynecologic/Obstetric Pathology |
| S1860S | Uterine, Ovarian, and Tubal Serous Carcinoma in the Female Genital Tract: Differential Diagnosis and Grading 9:00 AM – 11:00 AM CT |
Ann Folkins, MD Teri A. Longacre, MD, FCAP afolkins@stanford.edu, longacre@stanford.edu, phyllis2@stanford.edu |
Serous carcinoma in the female genital tract continues to be a problem area for diagnostic surgical pathologists. This course will address the distinction between: 1) uterine serous carcinoma and other histologic subtypes of endometrial cancer; 2) borderline and low-grade serous carcinoma; and 3) low-grade and high-grade serous carcinoma. These distinctions are important because patients are managed differently for each of these disease entities. The faculty will specifically provide diagnostic criteria, terminology, and the standardized reporting format for serous epithelial neoplasms (uterine/ovarian/tubal/peritoneal) with emphasis on use of ancillary studies, including p53 to improve diagnosis. Additionally, they will use a case-based approach, and the audience will then be able to interactively test their skills on another series of cases. Time for questions/discussions will follow each case. |
Sunday, October 11 | October 11 | 09:00 AM | 11:00 AM | Gynecologic/Obstetric Pathology |
| S1884S | Common Errors in Diagnosing Chronic Colitis and the Challenges of IBD-Associated Dysplasia 9:00 AM – 11:00 AM CT |
Amitabh Srivastava, MD, MBBS, FCAP ASrivastava@bwh.harvard.edu, doleary3@bwh.harvard.edu |
Establishing a diagnosis of chronic inflammatory bowel disease (IBD) can be challenging and has far-reaching clinical consequences. Every biopsy diagnosed as chronic colitis does not imply IBD, and IBD patients do not always show a chronic colitis on biopsy. Further, a diagnosis of IBD dysplasia may lead to interventions that vary from a simple polypectomy to continued surveillance to a total colectomy, depending on patient characteristics and endoscopy findings. Using a combination of lectures and slide discussion with digitally-scanned slides, the faculty will address the problem of IBD mimickers and the spectrum of dysplasia in IBD. In addition, faculty will focus on common errors and how misdiagnosis/miscommunication can be avoided by using a systematic approach to biopsy interpretation and standardized reporting nomenclature. |
Sunday, October 11 | October 11 | 09:00 AM | 11:00 AM | Gastrointestinal Pathology |
| S2006C | Cost-Effective Stepwise Risk Stratification of ER Positive Breast Cancer Patients Using Collaborative Biomarker and Molecular Testing 9:00 AM – 11:00 AM CT David G. Hicks, MD, FCAP |
David G. Hicks, MD, FCAP Bradley M. Turner, MD, MPH, MHA, FCAP david_hicks@urmc.rochester.edu, Cordelia_Smith@URMC.Rochester.edu, bradley_turner@urmc.rochester.edu |
The introduction of multigene assays and next-generation sequencing has increased our understanding of tumor biology and clinical behavior; however, the cost of these newer technologies is concerning. Although pathologists and clinicians practice competently with the available information, the increasing numbers of prognostic and predictive methodologies have created a knowledge gap regarding which testing methodologies are most informative and cost-effective for predictive and prognostic pathology. In this course, appropriate for any provider involved with risk stratification of breast cancer patients, the faculty will highlight molecular technologies for risk stratification of breast cancer patients. They will also focus on the cost-efficiency of these methods in comparison to standard histopathologic methodologies for risk stratification and discuss how a “step-wise” approach using traditional clinical-pathologic paradigms coordinated with molecular characterization of breast tumor tissue can be more cost-effective. |
Sunday, October 11 | October 11 | 09:00 AM | 11:00 AM | Breast Pathology |
| S2019S | Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies 9:00 AM – 11:00 AM CT |
M. Qasim Ansari, MD, FCAP David F. Keren, MD, FCAP mohammad.ansari@va.gov, dkeren@med.umich.edu |
The process for the detection of monoclonal gammopathies is highly complex. To obtain an accurate diagnosis, diagnostic data must be compiled from several areas of the laboratory (eg, total protein, immunoglobulin levels, gel or capillary electrophoreses patterns). In 2017, an Archives of Pathology & Laboratory Medicine survey highlighted a wide variation in testing and ordering practices for the initial screening for monoclonal gammopathies. This survey prompted the development of the evidence-based guideline recommendations for the laboratory detection and initial diagnosis of monoclonal gammopathies. The evidence-based guideline is focused on pathology-related key questions on the initial diagnosis of monoclonal gammopathies, beginning with how clinicians should order for testing when monoclonal gammopathies are suspected and ending with how pathologists should communicate the results of testing back to the clinician. The guideline scope also includes the reinforcement of the International Myeloma Working Group (IMWG) Criteria for Diagnosis of Multiple Myeloma for testing and reporting. |
Sunday, October 11 | October 11 | 09:00 AM | 11:00 AM | Immunology |
| S2039C | Blood Smears are Easy! A Morphology-Based Approach to Hematopoietic Neoplasms Presenting With an Abnormal WBC Differential 9:00 AM – 11:00 AM CT Kyle T. Bradley, MD, MS, FCAP |
Kyle T. Bradley, MD, MS, FCAP Olga Pozdnyakova, MD, PhD, FCAP kyle.bradley@emory.edu, opozdnyakova@bwh.harvard.edu |
Careful morphologic review of blood smears is a crucial first step in the diagnostic workup of an abnormal WBC differential. Are the changes reactive or neoplastic? What diagnostic pitfalls do I need to be aware of? Do I need to perform flow cytometry or other ancillary tests? Do not be intimidated! Join the faculty to learn a practical, morphology-based approach that will allow you to answer these questions confidently. They will utilize carefully selected cases to illustrate a variety of neoplastic conditions and benign mimics that present as neutrophilia, monocytosis, or lymphocytosis, and include an approach to evaluating smears flagged for blasts or “other” cells. The course emphasizes cost-effective application of ancillary studies and is appropriate for all pathologists and trainees who wish to improve their skill in evaluating blood smears. Who says blood smears are hard? |
Sunday, October 11 | October 11 | 09:00 AM | 11:00 AM | Hematology/Hematopathology |
| V1883C | Practical Issues in Testicular Pathology: A Case-Based Discussion 9:00 AM – 11:00 AM CT |
Muhammad T. Idrees, MD, FCAP Chia-Sui Kao, MD, FCAP midrees@iupui.edu, ckao2@stanford.edu |
This video microscopy course will focus on challenging differential diagnosis of testicular tumors. Faculty will emphasize pitfalls in tumor classification including, but not limited to, subclassification of germ cell tumors and differentiating sex cord-stromal tumors from germ cell tumors. Additionally, faculty will incorporate best practices in the application of IHC that will aid in resolving certain diagnostic challenges as well as a discussion of the most up-to-date American Joint Committee on Cancer staging information. |
Sunday, October 11 | October 11 | 09:00 AM | 11:00 AM | Genitourinary Pathology |
| L2096C | Gastrointestinal, Liver, and Pancreaticobiliary Neoplasms: Precursors and Progeny, Charting the Course 8:00 AM – 4:30 PM CT Jeffrey D. Goldsmith, MD, FCAP |
Jeffrey D. Goldsmith, MD, FCAP Raul S. Gonzalez, MD, FCAP Alyssa M. Krasinskas, MD, FCAP Joseph Misdraji, MD Michael S. Torbenson, MD Lysandra Voltaggio, MD Mary Kay Washington, MD, PhD, FCAP (Moderator) Jeffrey.Goldsmith@childrens.harvard.edu, rgonzal5@bidmc.harvard.edu, akrasin@emory.edu, jmisdraji@mgh.harvard.edu, Torbenson.Michael@mayo.edu, lvoltag1@jhmi.edu |
Both benign and malignant neoplasms of the tubular gastrointestinal (GI) tract, liver, and pancreatobiliary tract arise in the setting of inflammatory conditions. An understanding of the pathways from inflammatory/reactive states to benign neoplasia to malignancy is vital to a successful practice of GI pathology. Join Dr. Kay Washington and a team of renowned GI pathology experts as they navigate these pathways by providing a practical approach for diagnosing GI, liver, and pancreatobiliary entities. They will use case-based discussions to review the morphology, H&E differential diagnosis, application of IHC and molecular tests, and pathogenesis of related neoplasia. These experts will also cover implications on clinical therapies and communications with gastroenterology, surgery, and oncology colleagues to optimize patient care. This intermediate to advanced full-day course is targeted to an audience of practicing surgical pathologists, as well as trainees engaged in subspecialized training in GI pathology. The course utilizes both traditional didactic and novel interactive approaches to facilitate learning. |
Sunday, October 11 | October 11 | 08:00 AM | 04:30 PM | Gastrointestinal Pathology |
| A2090N | Advocacy Town Hall 12:00 PM – 1:00 PM CT Patrick E. T. Godbey, MD, FCAP |
Patrick E. T. Godbey, MD, FCAP Jonathan L. Myles, MD, FCAP Emily E. Volk, MD, MBA, FCAP |
This session will provide members with a better understanding of the scope of our advocacy agenda. The CAP continually works to expand the public policy impact of pathology at the federal and state levels of government by engaging members in advocacy efforts. By combining grassroots advocacy with events like our annual policy meeting, town hall meetings, and other forums, engaged members help strengthen the profession’s influence with policymakers. |
Sunday, October 11 | October 11 | 12:00 PM | 01:00 PM | Advocacy |
| A2093N | Current Payment Policy Challenges in Pathology Practice 1:30 PM – 2:30 PM CT |
Jonathan L. Myles, MD, FCAP mylesj@ccf.org |
Pathologists are often challenged by payment policy-related issues regarding the services they provide. It is important that pathologists better understand how Advocacy seeks to influence payment policies, why changes in reimbursement occur, and how to adapt within their practices. Workshop participants will gain knowledge and insight into the engagement opportunities available. The faculty will present payment policy information associated with Physician Fee Schedule valuation (that can influence payment policy development), Clinical Laboratory Fee Schedule Payment Reform (PAMA), emerging payment models, and other payment challenges and possible solutions. |
Sunday, October 11 | October 11 | 01:30 PM | 02:30 PM | Advocacy |
| M1979S | Vascular Changes in Lung Biopsies: When and What to Report 1:30 PM – 3:00 PM CT |
Frank Schneider, MD, FCAP Kristen L. Veraldi, MD, PhD frank.schneider@emory.edu, klv11@pitt.edu |
Surgical pathologists are often confronted with vascular abnormalities in lung biopsies. They may be the first to detect a vasculopathy but are not certain whether the features are clinically significant. They also may be asked to confirm a clinically-suspected vasculitis but are not certain whether the features seen suffice to support the clinical diagnosis. This course, jointly presented by a pulmonologist and a pathologist, illustrates the histopathologic features of common and uncommon vascular changes seen in lung biopsies. The faculty will show how to formulate succinct diagnostic comments that are of value to clinicians, and discuss the clinician’s before- and after-management thought process. |
Sunday, October 11 | October 11 | 01:30 PM | 03:00 PM | Pulmonary Pathology |
| M2023C | Reference Ranges for the Transgender Population 1:30 PM – 2:30 PM CT |
Matthew D. Krasowski, MD, PhD, FCAP mkrasows@healthcare.uiowa.edu |
Transgender is a term used to describe individuals who identify with a gender different from their sex recorded at birth. This course will define terminology and system barriers relevant to transgender health care. Common gender-affirming interventions such as hormonal therapy (eg, estrogen or testosterone) and surgery will be discussed and faculty will focus on the impact of gender-affirming therapy on laboratory tests. Over the last five years, publications of detailed studies illustrating how gender-affirming therapies impact laboratory tests has allowed for the determination of reference ranges for the transgender population. Faculty will discuss this published data and its application, including informatics challenges related to gender identity in the laboratory information system and electronic medical record. This course will illustrate how pathology plays a critical role in providing inclusive and evidence-based care for the transgender patient population. |
Sunday, October 11 | October 11 | 01:30 PM | 02:30 PM | Laboratory Medical Direction |
| M2040C | Clinical History: “Rash”: An Approach to Skin Biopsies Without a Clinical History 1:30 PM – 2:30 PM CT |
Anne M. Stowman, MD anne.stowman@uvmhealth.org |
Clinicopathologic correlation in making the diagnosis of dermatologic eruptions is essential. Too often however, the requisition arrives with clinical history “rash,” or worse, “L98.9” (skin disorder, NOS). Inflammatory skin disorders are numerous, frequently biopsied, and challenging to diagnose. Developing a systematic approach to these specimens is a practical and critical skill for all pathologists, particularly those in community practice where specimens may be coming from a number of subspecialty clinics and providers. The faculty will review the basic categories of eruptions (eg, spongiotic, lichenoid, psoriasiform), how to work up an inflammatory skin biopsy, and how to identify histologic clues to narrow the differential diagnosis. Additionally, the course will cover the short list of entities “not to be missed” and when reporting a differential diagnosis is appropriate. Finally, faculty will use a case-based presentation style to apply current knowledge and highlight subtleties within each case to use as a guide for clinical practice. |
Sunday, October 11 | October 11 | 01:30 PM | 02:30 PM | Dermatopathology |
| M2099C | Pathology Consultation: An Essential Component for Optimized Healthcare 1:30 PM – 2:30 PM CT |
Michael Laposata, MD, PhD, FCAP milaposa@utmb.edu, smhebert@UTMB.EDU |
Join us as Michael Laposata, MD, PhD, FCAP, describes how pathologists will move from behind the scenes experts providing mostly anatomic pathology to be the most prominent diagnostician who will synthesize all diagnostic information, generated inside and outside of pathology.
In the first half of the 20th century, pathologists revealed the pathogenesis for thousands of different diseases through autopsies of affected patients. The dependence of Sir William Osler on autopsy findings to improve diagnosis and treatment is legendary. The second half of the 20th century saw the development and optimization of surgical pathology and cytopathology, and that activity accounted for the majority of the work of most pathologists.
The first 50 years of the 21st century will include artificial intelligence capable of reading digitally-scanned glass slides. Pathologists in this current half century are perfectly positioned to provide much more than the microscopic review of glass slides, because we direct the laboratories that generate the vast majority of diagnostic information. Pathologists are moving toward a role that integrates all diagnostic studies including anatomic pathology, an increasingly complex clinical laboratory with much genetic data, imaging studies, and other disease-specific diagnostics. The faculty will focus on this growing indispensability for pathologists who provide an all-encompassing diagnostic report.
Dr. Michael Laposata is the professor and chair of the Department of Pathology at the University of Texas Medical Branch-Galveston. He received his MD and PhD from Johns Hopkins University School of Medicine and completed a postdoctoral research fellowship and residency in laboratory medicine (clinical pathology) at Washington University School of Medicine in St. Louis. He took his first faculty position at the University of Pennsylvania School of Medicine in Philadelphia in 1985, where he was an assistant professor and director of the hospital’s Coagulation Laboratory. In 1989, he became director of Clinical Laboratories at the Massachusetts General Hospital and was appointed to the faculty in the Department of Pathology at Harvard Medical School, where he became a tenured full professor of pathology. Dr. Laposata joined Vanderbilt University School of Medicine in 2008 where he was the Edward and Nancy Fody Professor of Pathology and Medicine. Additionally, he was pathologist-in-chief at Vanderbilt University Hospital and director of Clinical Laboratories. |
Sunday, October 11 | October 11 | 01:30 PM | 02:30 PM | Laboratory Medical Direction |
| S1868C | Cervical Adenocarcinoma: From AGUS to Zebras—Cytology and Histology of Usual Type Adenocarcinomas and Special Variants 9:00 AM – 11:00 AM CT |
Christina S. Kong, MD, FCAP Teri A. Longacre, MD, FCAP ckong@stanford.edu, longacre@stanford.edu, phyllis2@stanford.edu |
Are those reactive endocervical cells or am I missing adenocarcinoma in situ (AIS)? Is that pattern invasive adenocarcinoma or just extensive AIS? How do I measure invasion? What is iSMILE? Gastric-type adenocarcinoma? If you’ve struggled with these questions, join faculty for an interactive, case-based course addressing glandular lesions in cervical cytology, small biopsy specimens, and resection specimens. The faculty will review the: 1) newly-revised World Health Organization classification of endocervical adenocarcinomas based on human papilloma virus status and uncommon variants such as iSMILE and gastric-type; 2) 2018 changes to FIGO staging that eliminates horizontal extent as a criterion; 3) threshold criteria for distinguishing reactive changes from atypical glandular cells and adenocarcinoma in situ; and 4) pattern-based Silva classification system. |
Monday, October 12 | October 12 | 09:00 AM | 11:00 AM | Gynecologic/Obstetric Pathology |
| S1914S | Cytologic Atypia? Think Again! Using Updated Cytology Terminology to Minimize Cytologic Atypia and Improve Patient Management 9:00 AM – 11:00 AM CT |
Nirag C. Jhala, MD, FCAP Esther D. Rossi, MD, PhD Nirag.jhala@tuhs.temple.edu, esther.rossi@policlinicogemelli.it |
This course will highlight common cytologic challenges faced by general pathologists interpreting thyroid, salivary gland, and pancreatic fine-needle aspirations (FNAs) with a focus on reducing the interpretation of cytologic atypia. Faculty will use a case-based method to show participants how to approach challenging lesions and apply standardized reporting to improve patient outcome and direct subsequent care. The incorporation of new biopsy devices and endoscopic approaches, especially in pancreatic FNA, pose new challenges for pathologists that may increase atypical rates in practice. The faculty will demonstrate use of an algorithmic approach to minimize diagnoses of atypia. They will also demonstrate how new developments in needle technology, utilization of rapid onsite evaluation and ancillary studies, and understanding of sample acquisition can help avoid pitfalls in diagnosis. Cosponsored by the American Society of Cytopathology (ASC) |
Monday, October 12 | October 12 | 09:00 AM | 11:00 AM | Cytopathology |
| S1967S | Thriving in MIPS and Other Value-Based Payment Programs 9:00 AM – 11:00 AM CT |
Diana M. Cardona, MD, FCAP Emily E. Volk, MD, MBA, FCAP diana.cardona@duke.edu, emily.volk@icloud.com |
Pathologists could lose, or gain, $2.1 billion over seven years in Medicare’s new quality payment programs. This represents the difference between pathologists gaining the full possible Medicare payment bonuses or receiving the payment penalties. Pathologists need to understand Medicare’s merit-based incentive payment system (MIPS) program as it relates to reducing the burden of participating, understanding and maximizing scoring, and seeking measures and improvement activities with maximum scoring and bonus point potential. Decisions pathology practices make affect Medicare incentive payments. The faculty will help pathologists select reporting options, including understanding the potential benefits of group reporting, how reporting options can affect scoring, and how to choose the best reporting option. In addition, value-based payments may come from participating in alternative payment models and accountable care organizations. Demonstrating the value of pathology in these models is critical for ensuring pathologists receive fair and adequate recognition and payment. |
Monday, October 12 | October 12 | 09:00 AM | 11:00 AM | Practice Finance |
| S2008C | Pathology Engagement in Global Health: A Workshop for Exploring Opportunities to Get Involved 9:00 AM – 11:00 AM CT Jerad M. Gardner, MD, FCAP |
Jerad M. Gardner, MD, FCAP Allison Hall, MD, PhD, FCAP Xiaoyin “Sara” Jiang, MD, FCAP Dana M. Razzano, MD jmgardner@uams.edu, allison.hall@duke.edu, jiang009@mc.duke.edu, Dana.Razzano@gmail.com |
Global pathology is an area of increasing interest among pathology organizations, pathologists, laboratory medicine specialists, and pathology trainees alike. Opportunities abound, from short-term or telepathology options for those looking to help but are limited in time, or not looking/able to travel, to long-term partnerships and research collaborations. The average pathologist may not know about how to get involved or that there are so many different avenues of involvement. This workshop will introduce the value of participating in global pathology to pathologists at all levels, including trainees to seasoned physicians. A panel of pathologist faculty members and one resident will share personal experiences of global participation. The final portion of the workshop will review a spectrum of engagement avenues and allow time for audience questions and discussion. |
Monday, October 12 | October 12 | 09:00 AM | 11:00 AM | Building and Maintaining Relationships |
| S2012C | Hematopathology Alphabet Soup: ICUS, CCUS, CHIP, or MDS? Integrating Next-Generation Sequencing Into the Evaluation of Cytopenias – A Practical Primer 9:00 AM – 11:00 AM CT |
Jennifer B. Dunlap, MD, FCAP Philipp Raess, MD, PhD, FCAP dunlapj@ohsu.edu, raess@ohsu.edu |
Evaluation of patients with cytopenias includes clinical history, laboratory testing, and frequently bone marrow biopsy. Next-generation sequencing (NGS) is increasingly used in the evaluation of patients with cytopenias. However, mutations indicative of clonal hematopoiesis are also present in individuals without hematologic malignancies, creating a diagnostic challenge.
Using a case-based and interactive format, this session provides a practical approach for incorporation of NGS in the workup of patients with cytopenias. The faculty will present cases focused on basic concepts of NGS testing and clinical and pathologic relevance of frequently-identified mutations. Upon completion of this session, participants will to be able to accurately differentiate myelodysplastic syndromes (MDS), clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenias of uncertain significance (CCUS), and idiopathic cytopenias of undetermined significance (ICUS). Participants will also learn to generate relevant diagnostic reports and serve as effective consultants for their clinical colleagues. |
Monday, October 12 | October 12 | 09:00 AM | 11:00 AM | Hematology/Hematopathology |
| S2017C | ASCP-CAP-ASH Requirements for the Laboratory Workup of Lymphoma: An Evidence-Based Approach to an Accurate Diagnosis 9:00 AM – 11:00 AM CT Matthew Cheung, MD, FRCPC, SM |
Matthew Cheung, MD, FRCPC, SM Paul Davis Cordelia E. Sever, MD, FCAP matthew.cheung@sunnybrook.ca, padavis@nl.rogers.com, Cordelia.Sever@tricore.org |
Lymphoma diagnosis has evolved from morphologic evaluation with limited ancillary testing to the sophisticated application of IHC, flow cytometry, and molecular diagnostics to arrive at the correct diagnosis and enable actionable therapy. While surgical lymph node biopsy has been the gold standard for procuring an adequate specimen, clinical practice has shifted to smaller specimen types including needle biopsies, fine-needle aspirations, and cell blocks. Faculty will present the ASCP-CAP-ASH “Requirements for the Laboratory Workup of Lymphoma” guideline with recommendations for suitable types of specimens, requirements for ancillary testing, and clinical follow-up. They will also discuss good practice statements to address specimen handling, use of clinical information, result reporting, and peer review. The inclusion of a patient representative on the panel provides a dynamic format focusing the discussion on safety aspects, clinical scenarios that may be encountered, and practical considerations for implementation to ensure optimal patient outcomes. |
Monday, October 12 | October 12 | 09:00 AM | 11:00 AM | Hematology/Hematopathology |
| V1873C | Spectrum of Colitis, Dysplasia, and Cancer in Inflammatory Bowel Disease 9:00 AM – 11:00 AM CT |
Amitabh Srivastava, MD, MBBS, FCAP ASrivastava@bwh.harvard.edu, doleary3@bwh.harvard.edu |
This video microscopy tutorial will provide participants an opportunity to review the morphological features, differential diagnosis, and spectrum of atypia in inflammatory bowel disease (IBD). The faculty will discuss topics ranging from florid reactive change to dysplasia. The focus will be on morphologically distinctive phenotypes of dysplasia and cancer in IBD, and changes commonly seen in targeted biopsies obtained during surveillance colonoscopies using enhanced visualization techniques. |
Monday, October 12 | October 12 | 09:00 AM | 11:00 AM | Gastrointestinal Pathology |
| P2002N | COVID Testing: Symphony or Cacophony? 12:00 PM – 1:00 PM CT Kisha Mitchell-Richards, MD, FCAP (moderator) |
Kisha Mitchell-Richards, MD, FCAP (moderator) Ben Pinsky, MD, PhD Christina Wojewoda, MD, FCAP |
This year’s Scientific Plenary will focus on current and emerging methods, pitfalls and tradeoffs of various COVID testing methodologies. Attendees will gain insight and knowledge of how COVID testing has impacted everyday practice, comprehending the multiple testing options, and understanding their accuracy and reliability. Facilitated by Kisha Mitchell-Richards, MD, FCAP, the plenary also will feature Benjamin Pinsky, MD, PhD, FCAP, and Christina M. Wojewoda, MD, FCAP. Hear from our expert faculty: |
Monday, October 12 | October 12 | 12:00 PM | 01:00 PM | |
| M1916S | Small Specimens Great Outcomes: New CAP Guideline on Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies 1:30 PM – 2:30 PM CT |
Sinchita Roy-Chowdhuri, MD, PhD, FCAP sroy2@mdanderson.org |
With advances in minimally invasive thoracic sampling techniques, laboratories can perform multiple ancillary studies on small biopsy and cytology specimens to aid the diagnosis and management of pulmonary pathology. The new CAP guideline, Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies, provides recommendations for pathologists and proceduralists to optimize testing outcomes for patients with suspected thoracic abnormalities. The faculty will address factors such as needle gauge, number of passes, use of rapid onsite evaluation (ROSE), and collection media. |
Monday, October 12 | October 12 | 01:30 PM | 02:30 PM | Pulmonary Pathology |
| M1944S | Molecular Genomic Oncology for the Practicing Surgical Pathologist 1:30 PM – 2:30 PM CT |
C. Leilani Valdes, MD, FCAP Sophia L. Yohe, MD, FCAP leilani@valdes.net, yohe0001@umn.edu |
This case-based course is designed to help the busy practicing surgical pathologist deal with questions that arise regarding genomic testing for oncology specimens. The faculty will present practical approaches to real-life scenarios, including deciding how to choose between small targeted panels, large commercial panels with hundreds of genes, circulating tumor DNA testing, and how to select the best sample for testing. They will cover recommended testing for common solid tumors such as colorectal cancer, lung cancer, melanoma, brain tumors, and more, and will discuss when and how to test for microsatellite instability for both Lynch syndrome and immune therapy. Hear from our expert faculty: |
Monday, October 12 | October 12 | 01:30 PM | 02:30 PM | Genomics |
| M2021C | Better, Faster, Stronger: Technology Hacks to Improve Your Pathology Practice 1:30 PM – 2:30 PM CT Jerad M. Gardner, MD, FCAP |
Jerad M. Gardner, MD, FCAP Raul S. Gonzalez, MD, FCAP Xiaoyin “Sara” Jiang, MD, FCAP jmgardner@uams.edu, rgonzal5@bidmc.harvard.edu, jiang009@mc.duke.edu |
Technology moves at a fast pace, and many tools are available to streamline our practice. However, the busy pathologist may not have time to seek out and keep pace with all the latest developments and technologies. This course will be a one-stop shop for technology “hacks,” or shortcuts for our digital practice. Faculty will introduce or update pathologists at all levels and in all practice settings to digital tools freely or readily accessible to make their workflow faster and more efficient, saving time during sign-out, on projects, and at tumor boards. Additionally, they will cover hardware and software tips (such as image editing, cloud-based backup storage, and time-saving software shortcuts) and educational resources (such as websites and smartphone/tablet apps). |
Monday, October 12 | October 12 | 01:30 PM | 02:30 PM | Informatics |
| M2033C | Novel Hemophilia Therapies: Will These Medications Impact Coagulation Testing? 1:30 PM – 2:30 PM CT |
Andrew J. Goodwin, MD, FCAP David Unold, MD, FCAP andrew.goodwin@uvmhealth.org, dunold@ucdavis.edu |
Therapy for hemophilia patients is changing, and laboratory professionals should understand how these medications impact coagulation testing. During this course, participants will identify the novel hemophilia medications and describe their mechanisms of action. Additionally, the faculty will focus on biospecific monoclonal antibody therapy, which was recently approved for prophylactic use to reduce bleeding episodes in patients with hemophilia A, including those patients with a factor VIII specific inhibitors. Though these therapies are effective, laboratory testing is problematic, and the faculty will review cases designed to illustrate the impact of these novel therapies on coagulation assays. For laboratory physicians, it is critically important to recognize the potential limitations of the clot-based assays in patients receiving novel hemophilia therapies and provide appropriate guidance to clinical medical providers ordering laboratory testing in patients with hemophilia. |
Monday, October 12 | October 12 | 01:30 PM | 02:30 PM | Hemostasis Pathology |
| R2076C | Book Club: Bad Blood: Secrets and Lies in a Silicon Valley Startup 1:30 PM – 2:30 PM CT |
Paul Valenstein, MD, FCAP paul@valenstein.org |
New this year, CAP20 will feature a book club, which offers discussion of literature topics related to pathology in an intimate, small group setting.
Join Paul Valenstein, MD, FCAP, as he facilitates a conversation about John Carreyrou’s award-winning book, Bad Blood: Secrets and Lies in a Silicon Valley Startup. Attendees will read the book prior to the session and then engage in discussion to explore four themes:
1) Impact of innovation in the laboratory market space
2) Effect on medical directors who work in innovative clinical laboratories
3) Lessons to be drawn from the book’s main character and her experiences
4) Process of investigative journalism in the clinical laboratory industry and roles pathologists play.
Due to individual preferences for book formats, attendees will be responsible for securing their own book copy.
You will learn to:
• Discuss risks involved in clinical laboratory innovation.
• Recognize the types of pressure that may be applied to leaders in the clinical laboratory industry.
• Recognize responsibilities and response options when pressure is applied to medical leaders of clinical laboratories.
|
Monday, October 12 | October 12 | 01:30 PM | 02:30 PM | Laboratory Medical Direction |
| S1854S | The Interface of Cytology and Histology in Thyroid and Salivary Gland Pathology 9:00 AM – 11:00 AM CT |
Tarik M. Elsheikh, MD, FCAP Bruce M. Wenig, MD, FCAP elsheit@ccf.org, bruce.wenig@moffitt.org |
Thyroid and salivary gland neoplasms represent some of the most challenging surgical pathology and cytology cases encountered by pathologists today. Using a case-based format, this session will present a variety of diagnostically-challenging thyroid and salivary gland lesions from the consultation files of the speakers. Faculty will discuss differential diagnosis of follicular-patterned thyroid neoplasms, including the recently proposed terminology of noninvasive follicular thyroid neoplasm (NIFTP), criteria for capsular/vascular invasion, and minimal criteria for diagnosing papillary thyroid carcinoma. A practical diagnostic approach will be employed to evaluate salivary gland neoplasms, such as cellular benign neoplasms, basaloid tumors, and low intermediate-grade malignancies, with emphasis on potential pitfalls. The course also will provide updates on the Milan System for reporting salivary gland cytopathology and the Bethesda System for reporting thyroid cytopathology. |
Tuesday, October 13 | October 13 | 09:00 AM | 11:00 AM | Head and Neck Pathology |
| S1857S | Forget Your Unease With Interstitial Lung Disease: Top 10 Pearls to Change Your Practice Immediately 9:00 AM – 11:00 AM CT |
Brandon T. Larsen, MD, PhD, FCAP Maxwell L. Smith, MD, FCAP larsen.brandon@mayo.edu, smith.maxwell@mayo.edu |
When you see transbronchial or surgical lung biopsies, do you feel anxious and uneasy? If so, this course is for you. Based on years of experience with one of the highest-volume interstitial lung disease (ILD) consult practices in the US, faculty identified the top 10 pearls (in frequency and importance) that will change the way you practice and improve your product. The faculty will begin with an introduction to the current classification of ILD and how to approach the biopsy, and then use simulated cases that engage the audience and bring each critical pearl to life. Classifying fibrosing lung disease, acute lung injury, and granulomatous disease are a few of the important topics covered. Participants will leave with a specific list of pearls to use on their next ILD case. Cosponsored by the Pulmonary Pathology Society (PPS) |
Tuesday, October 13 | October 13 | 09:00 AM | 11:00 AM | Pulmonary Pathology |
| S1924S | Intraoperative Assessment of Pelvic Lesions in Female Patients: An Interactive Approach Using Cytology and Frozen Section Slides 9:00 AM – 11:00 AM CT |
Farnaz Hasteh, MD Somaye Y. Zare, MD fhasteh@ucsd.edu, syekezare@ucsd.edu |
Pelvic lesions submitted for frozen section intraoperative evaluation have very important implication for management as most are submitted for clinical suspicion of malignancy. While frozen section evaluation in pelvic organs is highly reliable, the implications are significant. The abundance of different types of pelvic lesions, often with overlapping features, makes accurate interpretation of them very challenging. This course is for general and specialized pathologists, as well as pathologists-in-training. Faculty will present an interactive approach and complete assessment of rapid cytology examination and correlation with frozen section slides of pelvic lesions with directed differential diagnosis. In addition, faculty will provide the tools to communicate the findings to clinicians and gynecologic oncologists, even in cases when a definitive diagnosis cannot be provided. |
Tuesday, October 13 | October 13 | 09:00 AM | 11:00 AM | Gynecologic/Obstetric Pathology |
| S1953S | A Glimpse into the Future Practice: Transitioning to an Effective Pathologist in the Age of Machine Learning 9:00 AM – 11:00 AM CT Anand S. Dighe, MD, PhD |
Anand S. Dighe, MD, PhD Barbara S. Ducatman, MD, FCAP Michael D. Feldman, MD, PhD Andrew R. Janowczyk, PhD asdighe@mgh.harvard.edu, barbara.ducatman@beaumont.org, michael.feldman2@uphs.upenn.edu, andrew.janowczyk@case.edu |
This course will provide a math-less foundation with enough information to equip any pathologist to become a purveyor of artificial intelligence and machine learning literature, sift through the crux of new studies and applications, and objectively identify less meaningful developments. The faculty will use real world examples from both anatomic pathology and laboratory medicine where machine learning has made inroads into the practice of pathology. Practical examples will allow attendees to speculate on potential new roles of pathologists and see how some former roles may become outmoded. Faculty also will focus on identifying where the value of new technologies is, how pathologists can add value over the technology, and what developments might occur in the next three to five years. This introductory course, sponsored by the Association of Pathology Chairs, will include exemplary presentations and time for audience engagement to address questions. Cosponsored by the Association of Pathology Chairs (APC) |
Tuesday, October 13 | October 13 | 09:00 AM | 11:00 AM | Informatics |
| S1965S | Fundamentals of Placenta Pathology: Keys to an Accurate Diagnosis 9:00 AM – 11:00 AM CT |
Michael A. Arnold, MD, PhD, FCAP Selene C. Koo, MD, PhD Michael.Arnold@ChildrensColorado.org, selene.koo@nationwidechildrens.org |
Placenta pathology and umbilical cord complications reportedly account for nearly two-thirds of fetal losses after 20 weeks gestation. Accurate diagnosis of placental pathology has implications for the baby, the mother, and her future pregnancies. An understanding of normal placenta gross anatomy and histology is essential to accurately identify gross and microscopic placental lesions associated with fetal injury. In particular, twin gestations present unique challenges, including specialized terminology, that are infrequently encountered by general pathologists. The faculty will emphasize the keys to performing an accurate gross examination of placentas and documenting a gross description using appropriate terminology. Participants will recognize diagnoses in placenta pathology by reviewing normal placenta histology and comparing normal histology with common pathologic conditions. |
Tuesday, October 13 | October 13 | 09:00 AM | 11:00 AM | Pediatric Pathology |
| S2009S | Let’s Get Serous About Fluid Cytology: Old Pitfalls and New Terminology! 9:00 AM – 11:00 AM CT |
Xiaoyin “Sara” Jiang, MD, FCAP Eva M. Wojcik, MD, FCAP jiang009@mc.duke.edu, ewojcik@lumc.edu, SGREEN@lumc.edu |
Understanding serous fluid cytology is foundational to practicing cytopathology, and new efforts are underway to standardize reporting. Faculty will present normal and abnormal components of fluids in a case-based session, with an emphasis on key cytomorphologic features and patterns seen in benign and malignant effusions. The session will introduce a practical algorithmic approach to serous effusions to help differentiate between different malignancies and reactive processes encountered in serous fluids. Faculty will also discuss ancillary studies, focusing on practical considerations and new diagnostic developments in malignant mesothelioma and their applications. The International System for Reporting Serous Fluid Cytology will be discussed to provide an algorithmic approach to reporting fluid cytology. Hear from our expert faculty: |
Tuesday, October 13 | October 13 | 09:00 AM | 11:00 AM | Cytopathology |
| V2086C | Hands-On Approach to Prostate and Bladder Biopsies 9:00 AM – 11:00 AM CT |
Mahul Amin, MD, FCAP Donna E. Hansel, MD, PhD, FCAP mamin5@uthsc.edu, hansel@ohsu.edu, josarah@ohsu.edu |
This video microscopy course will use a case-based approach to discuss common diagnostic scenarios in prostate and bladder biopsies and transurethral resection specimens. Topics include atypical prostate glands and distinction from small foci of prostate cancer, prostate cancer variants and reporting, flat urothelial lesions, mimickers of bladder neoplasia, and bladder cancer staging on limited specimens. The course is designed to maximize interaction between participants and instructors and involve the participants in discussion of the differential diagnosis and approach to diagnosis. |
Tuesday, October 13 | October 13 | 09:00 AM | 11:00 AM | Genitourinary Pathology |
| A2094N | COVID-19 Impacts on CAP-Accredited Laboratories 1:30 PM – 2:30 PM CT Kathleen G. Beavis, MD, FCAP |
Kathleen G. Beavis, MD, FCAP Joseph Sanfrancesco, MD, FCAP Thomas M. Wheeler MD, FCAP |
Attend this course to learn and share information about how CAP-accredited laboratories are dealing with issues arising from the COVID-19 pandemic. Dr. Thomas M. Wheeler, Chair of the CAP Policy Roundtable Steering Committee, will present data on how many CAP-accredited labs have been providing COVID-19 testing, the most signficiant problems these labs are facing in providing testing, and the economic and workforce pressures associated with the pandemic. Dr. Kathleen Beavis will provide the current perspective of testing from the standpoint an academic hospital lab, and Dr. Joseph Sanfransesco will discuss issues facing a smaller community practice located in the midst of the surge. There will be substantial time for the audience to share their experiences and to ask questions to the panel. |
Tuesday, October 13 | October 13 | 01:30 PM | 02:30 PM | Advocacy |
| M1872S | Papillary Lesions of the Breast 1:30 PM – 2:30 PM CT |
Xiaoxian (Bill) Li, MD, PhD, FCAP xli40@emory.edu |
Papillary breast lesions are commonly encountered in routine practice but can be challenging to diagnose. These lesions include papilloma with or without atypia (atypical papilloma), papilloma involved by ductal carcinoma in situ (DCIS), intraductal papillary carcinoma (papillary DCIS), encapsulated papillary carcinoma, solid papillary carcinoma, and invasive papillary carcinoma. Some of the papillary lesions are uncommon. General pathologists should be familiar with the morphology, ancillary studies, histopathological classification, and optimal treatment. In a recent study, 28% of 600 surveyed pathologists misclassified invasive papillary carcinoma as in situ carcinoma and 24% diagnosed encapsulated papillary carcinoma as invasive. This course aims to help pathologists become familiar with papillary lesions of the breast. |
Tuesday, October 13 | October 13 | 01:30 PM | 02:30 PM | Breast Pathology |
| M1971S | How is My Payment Determined for Pathology Services? 1:30 PM – 2:30 PM CT |
Jonathan L. Myles, MD, FCAP Mark S. Synovec, MD, FCAP mylesj@ccf.org, msss@aol.com |
Attend this course to learn about concepts of current procedural terminology (CPT) coding and payment for services on the Medicare Physician Fee Schedule (PFS). The faculty will provide an introduction and overview of how current coding and billing practices were developed and how the Centers for Medicare & Medicaid Services (CMS) values codes on the PFS. They will discuss how CPT codes are modified and the steps involved, and aspects of payment policy (eg, National Correct Coding Initiative (NCCI)). The existing process in the new value-based payment system will be examined and participants will gain an understanding of the changing payment and regulatory environment, how to anticipate future trends, and adapt their practice to current trends. |
Tuesday, October 13 | October 13 | 01:30 PM | 02:30 PM | Practice Finance |
| M2002C | Pathology of Vaping-Associated Lung Disease 1:30 PM – 2:30 PM CT |
Brandon T. Larsen, MD, PhD, FCAP Maxwell L. Smith, MD, FCAP larsen.brandon@mayo.edu, smith.maxwell@mayo.edu |
Are you familiar with the pathologic changes that occur in the lung in patients who “vape”? If not, this course is for you. Vaping has exploded in popularity in recent years, especially among young people. While initially marketed as a safe alternative to smoking and a method for smoking cessation, an epidemic of e-cigarette or vaping product use-associated lung injury (EVALI) has brought the risks of vaping into the national spotlight. In some cases, pathologists may be asked to evaluate biopsies or bronchoalveolar lavage fluid as part of an evaluation for EVALI. Faculty will begin with an introduction on vaping and review vape devices, contents, terminology, and associated epidemiology. Using a case-based format, they will share experiences with EVALI, review the spectrum of pathologic findings, and the role of the pathologist. Attendees will be provided with recommendations regarding specimen handling, ancillary testing, and reporting in this context. Cosponsored by the Pulmonary Pathology Society (PPS) |
Tuesday, October 13 | October 13 | 01:30 PM | 02:30 PM | Pulmonary Pathology |
| M2029C | Know Thy Clinician as Thyself 1:30 PM – 2:30 PM CT |
Gaurav Sharma, MD, FCAP David E. Willens, MD, MPH, FACP gsharma2@hfhs.org, DWILLEN1@hfhs.org |
When pathologists understand their clinicians’ needs, better decisions can be made by everyone. Communication is key – speaking face-to-face is better than email, Twitter, or just hoping everything will work out. If you are unsure of what is or is not important to clinicians, this session will help you become a better decision maker, collaborator, and increase your value to organizations. The faculty, an internist and a clinical pathologist, will help decipher the pains, gains, and priorities of the contemporary clinical team. |
Tuesday, October 13 | October 13 | 01:30 PM | 02:30 PM | Practice and Systems Integration |
| R2078C | Book Club: Bad Blood: Secrets and Lies in a Silicon Valley Startup 1:30 PM – 2:30 PM CT |
Paul Valenstein, MD, FCAP paul@valenstein.org |
New this year, CAP20 will feature a book club, which offers discussion of literature topics related to pathology in an intimate, small group setting.
Join Paul Valenstein, MD, FCAP, as he facilitates a conversation about John Carreyrou’s award-winning book, Bad Blood: Secrets and Lies in a Silicon Valley Startup. Attendees will read the book prior to the session and then engage in discussion to explore four themes:
1) Impact of innovation in the laboratory market space
2) Effect on medical directors who work in innovative clinical laboratories
3) Lessons to be drawn from the book’s main character and her experiences
4) Process of investigative journalism in the clinical laboratory industry and roles pathologists play.
Due to individual preferences for book formats, attendees will be responsible for securing their own book copy.
You will learn to:
• Discuss risks involved in clinical laboratory innovation.
• Recognize the types of pressure that may be applied to leaders in the clinical laboratory industry.
• Recognize responsibilities and response options when pressure is applied to medical leaders of clinical laboratories.
|
Tuesday, October 13 | October 13 | 01:30 PM | 02:30 PM | Laboratory Medical Direction |
| S1869S | Soft Tissue Pathology Is Fun…Really! A Crash Course for General Pathologists 9:00 AM – 11:00 AM CT |
Jerad M. Gardner, MD, FCAP Nicole D. Riddle, MD, FCAP jmgardner@uams.edu, nriddlemd@gmail.com |
This course provides a whirlwind—but thorough—tour of soft tissue pathology highlighting the most common entities, pitfalls, and appropriate ancillary testing usage. Faculty will cover topics including dermal-based, myxoid, and myoepithelial lesions, in addition to the usual adipocytic, neural, and myogenic entities. They also will provide a comprehensive update on selected topics pertinent to the everyday practice of pathology using a partial case-based approach and audience participation. Presentation of content will meet the needs of the pathologist in training and the more experienced general pathologist, as well as those interested in sharpening their soft tissue pathology skills. |
Wednesday, October 14 | October 14 | 09:00 AM | 11:00 AM | Soft Tissue Pathology |
| S1946S | Pearls and Pitfalls in the Interpretation of Endometrial Biopsies 9:00 AM – 11:00 AM CT |
Mamta Gupta, MD, MBBS, FCAP Ricardo R. Lastra, MD mgupta5@bidmc.harvard.edu, ricardo.lastra@uchospitals.edu |
Metaplastic changes (mucinous, eosinophilic, and papillary) associated with polyps and other benign conditions can be mistaken for neoplasia in endometrial biopsies. Moreover, several different nomenclatures are prevalent for reporting of endometrial precursor lesions (hyperplasia with and without atypia versus endometrioid intraepithelial neoplasia) and create important clinical issues in management. It is important for pathologists to render a correct diagnosis and be able to guide their surgical colleagues appropriately. The faculty will address common pitfalls in diagnosis, classification of endometrial precursor lesions and neoplasia, and describe uncommon and rare diagnoses that may be present in endometrial biopsy/curettage specimens. The faculty will also focus on key elements of a clinically-useful pathology endometrial biopsy report that facilitates better communication with the surgeons. |
Wednesday, October 14 | October 14 | 09:00 AM | 11:00 AM | Gynecologic/Obstetric Pathology |
| S1955S | Hot Issues in Clinical Chemistry and Immunology 9:00 AM – 11:00 AM CT |
D. Robert Dufour, MD, FCAP William E. Winter, MD, FCAP chemdoctorbob@earthlink.net, winter@pathology.ufl.edu |
This interactive and case-based course will cover areas where change is occurring and/or needed in chemistry and immunology. It is designed to address common problems related to interferences, as well as areas where use or interpretation of tests has evolved over time. Faculty will cover topics such as issues concerning high-sensitivity troponin testing, changes in lipid and diabetes guidelines, hyperkalemia in the outpatient setting, interferences in immunoassay testing, and hepatitis B reactivation. The format will allow pathologists to apply what they have learned to problem solving and enhance their ability to address common questions arising in academic and community-based clinical pathology settings. |
Wednesday, October 14 | October 14 | 09:00 AM | 11:00 AM | Laboratory Medical Direction |
| S2007C | CAP/ASCO Breast Cancer ER/PgR and HER2 Testing Guidelines: Latest Updates and Addressing Challenges 9:00 AM – 11:00 AM CT |
Kimberly H. Allison, MD, FCAP allisonk@stanford.edu |
In 2018 and 2019, the CAP and the American Society of Clinical Oncology (ASCO) updated their evidence-based guidelines for HER2 and ER/PgR testing for breast cancer. In order to help treating physicians determine proper patient treatment, pathologists must stay abreast of these essential tests, which drive decision-making. During this course, attendees will learn which recommendations stayed the same, which have changed and why, and how to troubleshoot the small percentage of “pesky” cases that cause the most turmoil (unusual HER2 ISH result groups, ER cases with low-positive staining, unusual/discordant results, and technical challenges). The faculty will also address other challenging areas. |
Wednesday, October 14 | October 14 | 09:00 AM | 11:00 AM | Breast Pathology |
| S2028C | Diagnostic Testing for Diffuse Gliomas: Claiming the Open Frontier 9:00 AM – 10:00 AM CT |
Daniel J. Brat, MD, PhD, FCAP daniel.brat@northwestern.edu |
The World Health Organization 2016 ushered in a new era in brain tumor diagnosis, including integrated molecular and morphologic classes of the diffuse gliomas. The new CAP guideline “Diagnostic Testing of Diffuse Gliomas” provides recommendations for genetic and molecular tests for pediatric and adult patients with diffusely-infiltrative gliomas. Based on a rigorous systematic review of more than 3,100 studies and a case-based approach, participants will better understand the recommended testing for each subtype – where the evidence is strong, benefits and pitfalls of various testing methodologies, and contexts where more than one testing strategy may be employed. Using this evidence-based guideline, both academic and community pathologists will be empowered to claim their laboratory’s stake on the diagnostic testing for diffuse gliomas open frontier. |
Wednesday, October 14 | October 14 | 09:00 AM | 10:00 AM | Medical Knowledge/Patient Care |
| A2092N | CPT Coding…You Can’t Practice Without It! Why Pathologists Need to Understand CPT Coding 1:30 PM – 2:30 PM CT |
Mark S. Synovec, MD, FCAP msss@aol.com |
Is understanding current procedural terminology (CPT) coding and its impact on your practice making your head spin? Get an insider expert’s insights and examples of current CPT coding practices and relevant payment policies for pathology and laboratory medicine. This workshop is designed to provide a comprehensive review of concepts as well as recent and anticipated changes in CPT coding that pathologists use to report their services.
Faculty also will address your CPT coding problems and direct you to additional resources for answering your coding and related payment policy questions.
|
Wednesday, October 14 | October 14 | 01:30 PM | 02:30 PM | NA |
| M2003C | The COVID-Transformed Autopsy Service: Guidelines From the Front Lines 1:30 PM – 2:30 PM CT Harold Sanchez, MD, FCAP |
Harold Sanchez, MD, FCAP Jonathan Thompson, MD, FCAP Alex K. Williamson, MD, FCAP |
COVID-19 has brought autopsy practice to the forefront of medical practice once again. While many have considered autopsy outdated and irrelevant, this pandemic has brought to attention the need for autopsy to aid our understanding of and guide therapy for emerging diseases. Many institutions and pathologists have experienced the challenge of dealing with autopsy and decedent management during this time. This hot topic course, intended for all academic and hospital-based pathologists, will describe ways in which different institutions have managed the autopsy service and decedent care during the COVID-19 pandemic. It has also brought the need for recording autopsy findings in a systematic format to facilitate sharing of data and global health efforts. As such, presenters will share ways in which autopsy services can use shared information to adapt to these challenges. |
Wednesday, October 14 | October 14 | 01:30 PM | 02:30 PM | |
| M2005C | Clinical Decision Support: The Pathologist’s Secret Weapon to Improve Patient Care and Avoid Adverse Events 1:30 PM – 2:30 PM CT Ronald Jackups Jr., MD, PhD, FCAP |
Ronald Jackups Jr., MD, PhD, FCAP agblouin@gmail.com, rjackups@wustl.edu |
Clinical decision support (CDS) systems are IT-based tools that compile patient- and context-specific data, presenting this to providers at the point-of-care and clinical decision making. CDS system tools can address a wide array of steps in the clinical care process (such as suggesting appropriate lab tests or alerting for potential drug-drug interactions) with the goal of improving care quality and avoiding adverse events. With regulatory focus on expanding health IT over the past decade, most institutions have implemented electronic health records (EHRs) and associated CDS as part of participation in government incentive programs. The laboratory plays a critical role in CDS systems, as the rules of CDS guide lab ordering and are driven by laboratory and pathology results. The laboratory medical director is an integral champion in the effective implementation and troubleshooting of CDS in laboratory and pathology ordering, providing expertise in results interpretation and test utilization. Therefore, knowledge of the applications and limitations of CDS is necessary to the practice of pathology. |
Wednesday, October 14 | October 14 | 01:30 PM | 02:30 PM | |
| M2042C | The Use of Feces to Cure Disease 1:30 PM – 2:30 PM CT |
colleen.kraft@emory.edu |
Wednesday, October 14 | October 14 | 01:30 PM | 02:30 PM | ||
| V1989C | Papillary and Spindle Cell Lesions of the Breast: A Case-Based Discussion With Emphasis in Differential Diagnosis and Pitfalls 1:30 PM – 2:30 PM CT |
xli40@emory.edu |
Wednesday, October 14 | October 14 | 01:30 PM | 02:30 PM |